Retatrutide Side Effects: What the Phase 2 Trial Reported

By DoseGauge Editorial · Updated 2026-06-12 · 4 min read

In the NEJM Phase 2 obesity trial, the most common side effects of retatrutide were gastrointestinal: nausea, diarrhea, vomiting, and constipation. The trial reported these events as dose-related and mostly mild to moderate in severity. Retatrutide is investigational and not FDA-approved as of June 2026, so this profile comes from trial data, not an approved label. That distinction matters: there is no FDA prescribing information listing adverse reactions, only the events recorded in published studies.

What the trial reported

The Phase 2 trial (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity to retatrutide at several target doses or placebo for 48 weeks. The paper reports that the most common adverse events in the retatrutide groups were gastrointestinal, that they were dose-related, and that they were mostly mild to moderate in severity. The named gastrointestinal events were nausea, diarrhea, vomiting, and constipation, the same category that recurs across incretin-based drugs.

Dose-related means the events were reported more often in the higher-dose arms than the lower ones. The trial used a weekly escalation (starting at 2 mg and stepping up every 4 weeks) in part to manage this, since gastrointestinal effects in this drug class tend to cluster around the early weeks and around each dose increase. The published report also noted dose-dependent increases in heart rate, which were described as transient. These are the trial's recorded observations, presented here without any judgment about how a given person would tolerate the drug.

A trial adverse-event table is a count of what happened in a controlled study with a defined population, defined doses, and monitoring. It is not a complete catalog of every possible effect, and it does not predict frequency or severity for anyone outside that study.

No FDA label yet

Approved drugs carry an FDA label with a standardized adverse-reactions section. Retatrutide does not have one, because it is investigational and not approved for any indication as of June 2026. Phase 3 trials under the TRIUMPH programme are ongoing, with topline data from some studies beginning to read out, but no FDA application or approval has been completed.

Practically, that means the safety picture for retatrutide is narrower and earlier than for an approved GLP-1 drug. It rests on Phase 2 data plus accumulating Phase 3 results, not on a finalized label, post-marketing surveillance, or the broad real-world use that approved drugs have. Anyone reading about retatrutide side effects is reading trial findings, not regulatory conclusions about safety.

What this means for dosing

The trial's escalation schedule (2 mg, then 4 mg, then 8 mg, then 12 mg, each held about 4 weeks) was structured the way incretin trials usually are: a low start and gradual increases, which the literature ties to limiting early gastrointestinal effects. That is a description of the trial's design rationale, not a recommendation to escalate, and not a claim that escalation prevents side effects.

If you are modeling the trial doses, the calculator converts a milligram dose into the units to draw at your reconstitution concentration. It performs arithmetic on the numbers you enter. It does not assess tolerability, does not recommend a dose, and makes no claim about whether any dose is safe for you.

Frequently asked questions

What are the most common retatrutide side effects?

In the NEJM Phase 2 obesity trial, the most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and constipation. The trial described them as dose-related and mostly mild to moderate. This reflects trial data, not an FDA label, because retatrutide is investigational.

Does retatrutide have an FDA safety label?

No. Retatrutide is not FDA-approved as of June 2026, so there is no FDA prescribing information or approved adverse-reactions section. The available safety data comes from published trials, with Phase 3 (TRIUMPH) ongoing.

Were the side effects worse at higher doses?

The trial reported the gastrointestinal adverse events as dose-related, meaning they were recorded more often in higher-dose arms. The report also noted transient, dose-dependent heart-rate increases. These are trial observations for that study population and do not predict any individual's experience.

Is retatrutide safe?

That is not a question this page can answer. Retatrutide is investigational with no FDA label, and safety for any individual is a clinical judgment. What exists is published trial data describing the adverse events recorded under study conditions. Discuss any decision with a licensed clinician.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.